News & Updates

In the treatment of patients with rifampicin-resistant tuberculosis, a 6-month oral regimen consisting of bedaquiline, pretomanid, linezolid, and moxifloxacin (BPaLM) is safe and efficacious and compares favourably with standard of care, as shown in the final data from the phase IIB-III TB-PRACTECAL study.

Both mepolizumab and benralizumab are effective in improving the clinical outcomes of patients with severe eosinophilic asthma, as shown in a recent study. However, treatment with benralizumab appears to be better than mepolizumab in reducing exacerbations, improving forced expiratory volume, and depleting blood eosinophils.

Updates from two MARIPOSA trials presented at ESMO Asia 2023 underpin the potential of amivantamab-based regimens for the treatment of locally advanced or metastatic EGFR-mutated non-small cell lung cancer (EGFRm NSCLC) in Asian subgroups.

In Singapore, about one in six children and young persons (CYPs) developed long COVID, with persistence of ≥1 symptoms 3 months after an acute COVID-19 infection, a survey study suggests.

In patients who are hospitalized for COVID-19, treatment with empagliflozin does not appear to have any positive impact on outcomes such as 28-day mortality, duration of hospital stay, or risk of progressing to invasive mechanical ventilation or death, as shown in the open-label RECOVERY trial.